Editor-in-Chief Hatice Kübra Elçioğlu Vice Editors Levent Kabasakal Esra Tatar Online ISSN 2630-6344 Publisher Marmara University Frequency Bimonthly (Six issues / year) Abbreviation J.Res.Pharm. Former Name Marmara Pharmaceutical Journal
Journal of Research in Pharmacy 2023 , Vol 27 , Issue Supp.
PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES
Eva María DOMÍNGUEZ-MARTÍN1,Mariana MAGALHÃES3,Przemysław SITAREK7,Ana María DÍAZ-LANZA2,Ana M. GÓMEZ8,Thomas EFFERTH9,Célia CABRAL5,Patricia RIJO1
1Center for Research in Biosciences & Health Technologies (CBIOS), Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, Lisbon, Portugal
2Universidad de Alcalá de Henares. Facultad de Farmacia, Departamento de Ciencias Biomédicas, Madrid, España
3PhD Programme in Experimental Biology and Biomedicine, Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa Costa Alemão, Coimbra, Portugal
4CNC—Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
5Faculty of Medicine, Clinic Academic Center of Coimbra (CACC), Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
6Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
7Department of Biology and Pharmaceutical Botany, Medical University of Lodz, Lodz, Poland
8Instituto de Química Orgánica, IQOG-CSIC, Juan de la Cierva 3, Madrid, Spain
9Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
10Centre for Functional Ecology, Department of Life Sciences, University of Coimbra, Calçada Martim de Freitas, Coimbra, Portugal
11Instituto de Investigação do Medicamento (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal
DOI : 10.29228/jrp.381 Cancer is one of the main causes of morbidity and mortality worldwide. Glioblastoma- GBM is the most malignant variant of intrinsic glial brain tumors. The treatments available entailed surgical resection followed by temozolomide chemotherapy and/or radiotherapy, which are associated with multidrug resistance, severe side effects, relapse and reduced survival. Therefore, new therapeutic approaches are needed to overcome these problems [1].

Natural products are an important source of bioactive lead molecules. The genus Plectranthus (Lamiaceae family) is known to be rich in diterpenes abietane-type royleanones (such as 7α- acetoxy-6β-hydroxyroyleanone (Roy), 7β,6β-dihydroxyroyleanone (DiRoy), 6,7- dehydroroyleanone (DeRoy) and Parviflorone D (ParvD)) which possess, among others, antitumoral properties. The cytotoxic effect of these royleanones is due to their pro-apoptotic nature, which results, for example, in exert their activity in primary H7PX glioma cells by DNA double-strand breaks and G2/M cell cycle arrest [2]. Among the mentioned royleanones, Roy and DiRoy are frequently found in the extracts of the species P. hadiensis var. hadiensis Schweinf. and P. grandidentatus Gürke.

Recently, we described the bioguided isolation of compounds from the acetonic extract of P. hadiensis stems and investigated the in vitro antiglioblastoma activity of the extract and its isolated constituents. After extraction, six fractions were obtained. Fractions V and III showed the highest antioxidant and antimicrobial activities. None of the fractions were toxic in the Artemia salina assay. It was isolated the abietane-type diterpenes Roy and DiRoy, which was also in agreement with the HPLC-DAD profile of the extract. The antiproliferative activity evaluation by Alamar blue assay evidenced that after 48 h treatment, Roy exerted strong antiproliferative/cytotoxic effects against tumor cells with low IC50 values among the different glioblastoma cell lines (U87, A172, U118, U373 and H4). Moreover, it was synthesized a new fluorescence derivative to evaluate the biodistribution of Roy. The uptake of BODIPY-7α-acetoxy-6β-hydroxyroyleanone by GB cells was associated with increased intracellular fluorescence, supporting the antiproliferative effects of Roy [3].

In conclusion, Roy is a promising lead compound to generate semisynthetic derivatives in order to its potential to be used as Active Pharmaceutical Ingredient (API) to develop new pharmaceutical formulations. Further studies should be performed to unveil the mechanism of action of Roy active against GB, which appears to be due to its accumulation in cytoplasmic vesicles and to the induction of mitochondria dependent intrinsic pathway apoptosis. Keywords : Glioblastoma, Lamiaceae, Plectranthus, diterpenes, royleanones

Marmara University